IPP Bureau
Touchlight & NEB launch game-changing benchtop DNA kit
By IPP Bureau - March 20, 2026
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
MedRabbits launches integrated clinic to revolutionize patient care
By IPP Bureau - March 20, 2026
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
By IPP Bureau - March 20, 2026
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
By IPP Bureau - March 20, 2026
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Roche breaks lab barriers as FDA clears mass spec tests for wider use
By IPP Bureau - March 20, 2026
The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio
SK bioscience bags fresh backing to accelerate fight against respiratory disease
By IPP Bureau - March 20, 2026
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
By IPP Bureau - March 20, 2026
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI
By IPP Bureau - March 20, 2026
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients
By IPP Bureau - March 20, 2026
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Glenmark Therapeutics USA launches fluticasone propionate nasal spray
By IPP Bureau - March 20, 2026
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets
By IPP Bureau - March 20, 2026
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
Epigenica expands into Japan via PrimeTech partnership
By IPP Bureau - March 20, 2026
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
LANXESS marks 40 yrs of animal disease defense 'Virkon S'
By IPP Bureau - March 20, 2026
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
Clariant boosts US pharmaceutical production with Clear Lake expansion
By IPP Bureau - March 20, 2026
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
